Inclusion Criteria:

- Advanced/metastatic solid tumors for which no standard therapy exists

- ECOG (WHO) performance status 0-1

- Life expectancy of at least 3 months

- Age ≥ 18 years

- Adequate liver, pancreas and renal function

- Acceptable hematologic status

- Acute toxic effects from prior therapy must be resolved to NCI CTCAE Grade ≤ 1

- Treatment with surgery, chemotherapy, or investigational therapy must be completed at
least one month prior to treatment initiation (6 weeks for nitrosoureas or Mitomycin
C and liposomal doxorubicin)

- Prior radiation therapy allowed in no more than 25% of bone marrow reserve

- Men and women of child-producing potential must agree upon the use of effective
contraceptive methods

Exclusion Criteria:

- In the past 6 months: myocardial infarction, unstable angina, coronary/peripheral
artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident
or transient ischemic attack, pulmonary embolism, deep vein thrombosis

- Known brain metastases

- Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy

- Pregnant or breast feeding women

- Known infection with HIV, active hepatitis B or hepatitis C

- Patients who have exhibited allergic reactions to a similar structural compound,
biological agent, or formulation

- History of pancreatitis or disorders making the patient at risk of pancreatitis

- Previous history or current presence of neurological disorders

- Patients with pre-existing symptoms of peripheral neuropathy not related to prior
anticancer therapy(ies)

- Concomitant treatment that may be associated with peripheral neuropathy

- Other severe concurrent conditions that could compromise protocol objectives.